Patents by Inventor Nicolai Wagtmann

Nicolai Wagtmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
    Publication number: 20210317223
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 14, 2021
    Inventors: Mitchell Bigelow, Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
    Publication number: 20210261668
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 26, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Dhruv Kam Sethi, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • Siglec-10 antibodies
    Patent number: 11083785
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 10, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Laurent Gauthier, Benjamin Rossi, Nicolai Wagtmann
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20210238285
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 5, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • Siglec neutralizing antibodies
    Patent number: 11078274
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Benjamin Rossi, Nicolai Wagtmann
  • PROTEINS BINDING NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
    Publication number: 20210221894
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen on tumor cells, or an antigen on myeloid-derived suppressor cells or tumor-associated macrophages are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 22, 2021
    Inventors: Mitchell Bigelow, Gregory P. Chang, Ann F. Cheung, Jean-Marie Cuillerot, Jinyan Du, Asya Grinberg, William Haney, Steven O'Neil, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16, AND METHODS OF USE
    Publication number: 20210198369
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.
    Type: Application
    Filed: August 7, 2019
    Publication date: July 1, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20210122821
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 29, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
    Publication number: 20210079102
    Abstract: Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.
    Type: Application
    Filed: February 8, 2019
    Publication date: March 18, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Eva Gutierrez, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10870700
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 22, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Denis, Carine Paturel, Nicolai Wagtmann
  • SIGLEC-9-NEUTRALIZING ANTIBODIES
    Publication number: 20200369765
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN, LAURENT GAUTHIER
  • COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
    Publication number: 20200369764
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20200332008
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 22, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20200299383
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20200231679
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: August 23, 2018
    Publication date: July 23, 2020
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz, Nicolai Wagtmann, Jinyan Du
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10711063
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
    Publication number: 20200216544
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 9, 2020
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Dhruv Kam Sethi, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 10676523
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: June 9, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • TREATMENT OF CANCERS USING ANTI-NKG2A AGENTS
    Publication number: 20190322744
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 24, 2019
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE SOULAS, NICOLAI WAGTMANN
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 10329348
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 25, 2019
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann